|
Dialysis Modalities Show Similar Outcomes in AKI - Renal and Urology News |
 |
 |
April 14, 2015
Research revealed no significant difference in the risk of death between continuous renal replacement therapy and extended daily dialysis.
Data from randomized controlled trials show that extended daily dialysis and continuous renal replacement therapy for acute kidney injury (AKI) are associated with similar outcomes, according to the authors of a recently published meta-analysis.
Extended daily dialysis (EDD) was associated with decreased mortality compared with continuous renal replacement therapy (CRRT) in observational studies, but such studies are potentially subject to allocation or selection bias, researchers reported online ahead of print in the American Journal of Kidney Diseases.
A team led by Rinaldo Bellomo, MD, PhD, Austin Health, Heidelberg, Victoria, Australia, analyzed data from 17 studies: 7 randomized controlled trials (RCTs) and 10 observational studies. The 17 studies included 634 patients undergoing EDD and 574 undergoing CRRT.
RCTs revealed no significant difference in the risk of death between EDD and CRRT, but observational studies show that EDD was associated with a 16% decreased relative risk of mortality compared with CRRT.
Both the RCTs and observation studies demonstrated no significant difference between the modalities with respect to kidney recovery, fluid removal, length of stay in the intensive care unit, and laboratory findings (serum urea, serum creatinine, and serum phosphate).
The investigators stated that, to their knowledge, their study is the first to systematically evaluate the effect of EDD versus CRRT on patients with AKI.
|
|
Repeat Prostate Biopsies Find Significant Cancers - Renal and Urology News |
|
|
April 14, 2015
Researchers found an increased likelihood of prostate cancer with fourth repeat biopsy and in patients older than 70.
(HealthDay News) -- Among a group of men with an initial negative prostate biopsy, clinically significant cancer is still found in subsequent repeat sampling rounds, according to a study published in the April issue of The Journal of Urology.
Nitya E. Abraham, M.D., from the New York University School of Medicine in New York City, and colleagues collected data on 1,837 men who underwent prostate biopsy (Jan. 1, 1995, to Jan. 1, 2010). The authors sought to determine characteristics of repeat biopsy (indication for biopsy, the number of repeat biopsies performed, the number of cores obtained, and total prostate-specific antigen before biopsy), as well as features of prostate cancer diagnosed on repeat biopsy (including Gleason score, number of positive cores, percent of tumor and treatment choice).
The researchers found that 1,213 men had negative initial biopsies, but that 798 repeat biopsies were performed in 255 men. Gleason score was ?6 in 33 of 63 men diagnosed with prostate cancer, 7 in 22, and 8 to 9 in 8 men. Using Epstein criteria, the rate of clinically insignificant cancer diagnosis decreased substantially by the third and fourth repeat biopsies. An increased likelihood of prostate cancer diagnosis was seen in men ?70 years with repeat biopsies, biopsies including more than 20 cores, and the fourth repeat biopsy.
"Given the continued likelihood of cancer detection even by the fifth biopsy, early consideration of saturation or image guided biopsy may be warranted in the repeat biopsy population," the authors write.
One author disclosed financial ties to the pharmaceutical and medical device industries.
Source
- Abraham, NE, et al. The Journal of Urology; doi: http://dx.doi.org/10.1016/j.juro.2014.10.084.
|
|
|
NxStage Kidney Care Brings Dialysis Options to Pittsburgh Area - MarketWatch |
|
|
LAWRENCE, Mass., April 14, 2015 /PRNewswire/ -- NxStage® Kidney Care, Inc., a subsidiary of NxStage Medical, Inc.
NXTM, -0.16%
today announced the opening of its Monroeville, Pennsylvania dialysis center, offering local patients several flexible therapy options. Conveniently located in Allegheny County, the NxStage Kidney Care Pittsburgh team is comprised of highly trained medical staff committed to providing dialysis patients with high quality, personalized and compassionate care.
The new facility offers customized therapy options using the NxStage System One™, including home hemodialysis (HHD), home nocturnal hemodialysis, flexible in-center hemodialysis, and short-term respite care. Additionally, the center offers peritoneal dialysis (PD) therapy. All NxStage Kidney Care centers feature comprehensive home dialysis training tailored to the unique needs of each patient.
"We make home dialysis training and education about treatment options a focus here. Our goal is to work with patients to help them optimize their lives outside of dialysis," said Dr. Subramoniam Jayakumar, Medical Director at NxStage Kidney Care Pittsburgh. "Our approach to patient care focuses on each patient's individual needs, and together we develop a therapy plan that is safe, effective, and flexible."
Like all NxStage Kidney Care facilities, the center is furnished with modern, comfortable amenities, offering a quiet and relaxed environment. A renal social worker provides education and guidance throughout the kidney transplant process, and a dietitian works with patients to craft personalized nutritional plans.
NxStage Kidney Care Pittsburgh invites local patients and their families to an educational session on Chronic Kidney Disease (CKD) and treatment options, including those offered at the center. Patients interested in attending the event can call the center at (412) 224-5757 for details or visit www.nxstagekidneycare.com/locations/pittsburgh.
NxStage Kidney Care Pittsburgh is located at 3623 William Penn Highway, Monroeville, PA 15146. For more information about NxStage Kidney Care's home and flexible in-center dialysis options please visit www.nxstagekidneycare.com.
About NxStage Kidney Care
NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc.
NXTM, -0.16%
is innovating a dialysis care model that is intended to support and encourage patient centered care and provide enhanced access to the life-changing benefits of home therapy as well as flexible in-center options. By leveraging NxStage's home leadership and the innovative technology of its System One, NxStage Kidney Care is committed to helping patients take control of their dialysis and to allowing physicians the flexibility to prescribe what is truly best for their patients. For more information, please visit www.nxstagekidneycare.com or call (866) 694-2707.
About NxStage MedicalNxStage Medical, Inc.
NXTM, -0.16%
is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Media contact:
Kristen K. Sheppard, Esq.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: (978) 332-5923
Logo- http://photos.prnewswire.com/prnh/20141008/150974
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-kidney-care-brings-dialysis-options-to-pittsburgh-area-300065141.html
SOURCE NxStage Kidney Care, Inc.
Copyright (C) 2015 PR Newswire. All rights reserved
|
|
APOL1 gene variants associated with renal allograft failure - Nature.com |
|
|
|
 APOL1 gene variants associated with renal allograft failure
Nature.com
Kidneys recovered from deceased African American donors with two APOL1 nephropathy risk variants are at increased risk of renal allograft failure after transplantation, say researchers. A single-centre study published in 2011 showed that kidneys coming ...
|
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
